Human megakaryocytic microparticles induce de novo platelet biogenesis in a wild-type murine model
Open Access
- 2 March 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (5) , 804-814
Abstract
Platelet transfusions are used to treat idiopathic or drug-induced thrombocytopenia. Platelets are an expensive product in limited supply, with limited storage and distribution capabilities because they cannot be frozen. We have demonstrated that, in vitro, human megakaryocytic microparticles (huMkMPs) target human CD34+ hematopoietic stem and progenitor cells (huHSPCs) and induce their Mk differentiation and platelet biogenesis in the absence of thrombopoietin. In this study, we showed that, in vitro, huMkMPs can also target murine HSPCs (muHSPCs) to induce them to differentiate into megakaryocytes in the absence of thrombopoietin. Based on that, using wild-type BALB/c mice, we demonstrated that intravenously administering 2 × 106 huMkMPs triggered de novo murine platelet biogenesis to increase platelet levels up to 49% 16 hours after administration. huMkMPs also largely rescued low platelet levels in mice with induced thrombocytopenia 16 hours after administration by increasing platelet counts by 51%, compared with platelet counts in thrombocytopenic mice. Normalized on a tissue-mass basis, biodistribution experiments show that MkMPs localized largely to the bone marrow, lungs, and liver 24 hours after huMkMP administration. Beyond the bone marrow, CD41+ (megakaryocytes and Mk-progenitor) cells were frequent in lungs, spleen, and especially, liver. In the liver, infused huMKMPs colocalized with Mk progenitors and muHSPCs, thus suggesting that huMkMPs interact with muHSPCs in vivo to induce platelet biogenesis. Our data demonstrate the potential of huMkMPs, which can be stored frozen, to treat thrombocytopenias and serve as effective carriers for in vivo, target-specific cargo delivery to HSPCs.Keywords
This publication has 40 references indexed in Scilit:
- Three-Stage Ex Vivo Expansion of High-Ploidy Megakaryocytic Cells: Toward Large-Scale Platelet ProductionTissue Engineering Part A, 2013
- Lipid nanoparticles for hepatic delivery of small interfering RNABiomaterials, 2012
- Role of tumor suppressor p53 in megakaryopoiesis and platelet functionExperimental Hematology, 2012
- The spectrin-based membrane skeleton stabilizes mouse megakaryocyte membrane systems and is essential for proplatelet and platelet formationBlood, 2011
- In Vitro Megakaryocyte Production and Platelet Biogenesis: State of the ArtTransfusion Medicine Reviews, 2010
- Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticlesBlood, 2009
- Tumor Suppressor Protein p53 Regulates Megakaryocytic Polyploidization and ApoptosisJournal of Biological Chemistry, 2008
- The biogenesis of platelets from megakaryocyte proplateletsJournal of Clinical Investigation, 2005
- Presence of hematopoietic stem cells in the adult liverNature Medicine, 1996
- Biodistribution of pH-sensitive immunoliposomesBiochimica et Biophysica Acta (BBA) - General Subjects, 1986